Facebook
X
LinkedIn
ForwardThis educational resource is intended to provide healthcare professionals with the tools to aid in the treatment and management of adverse events in patients with relapsed refractory multiple myeloma.
Working in collaboration with
Video Introduction
This video covers the the topic of clinical management of treatment-related adverse events in relapsed/refractory multiple myeloma
Learning Activities
This is the core of the hub: a set of activities designed to build on each other, covering the clinical questions that come up most often in practice. Work through them in whatever order suits you and pick up where you left off, and where CME/CE credit is available, you'll see it noted on the activity itself.
Relapsed Refractory Multiple Myeloma
A course that looks at MM, and RRMM in detail and features a panel discussion between experts on MM & RRMM.
Optimizing Outcomes in RRMM: Personalized Approaches and Adverse Event Management
The video features leading experts discussing the latest advancements and challenges in treating multiple myeloma, focusing on therapies like CAR-T cells and bispecific antibodies.
Supplementary Materials
The learning doesn't stop at the activities. Here you'll find infographics that make the key data easy to take in at a glance, coverage from the conferences shaping this field, and reports that go deeper on the evidence. Save them, revisit them, or share them with colleagues who'd find them useful.
Relapsed Refractory Multiple Myeloma Treatment
By proactively preventing adverse events and effectively managing side effects, clinicians canleverage emerging treatments to achieve substantial survival benefits for patients with RRMM.
Meet the Faculty
Meet our Editorial Panel who are the key opinion leaders in the field of Multiple Myeloma. This expert panel brings you an independent educational hub where you can get resources on the latest advancements in research and treatment policies/guidelines in the field of Multiple Myeloma.
Suzanne Lentzsch
Professor of Medicine and Director, Multiple Myeloma and Amyloidosis Service, Columbia University Irving Medical Center, New York
Dr. Lentzsch leads the Multiple Myeloma and Amyloidosis Service at Columbia University, focusing on translational research to identify novel treatment targets for multiple myeloma (MM), MM bone disease, and AL amyloidosis. She is the Co-Chair of the NCI Myeloma Steering Committee and holds membership positions in various prominent hematology committees, including the ASH Scientific Committee for Plasma Cell Neoplasia and the SWOG Myeloma Working Group. Additionally, Dr. Lentzsch co-chairs the Career Development Committee of the International Myeloma Society and serves as Associate Editor for the Journal of Clinical Oncology and on the Editorial Board for Blood Cancer Discoveries.
Shaji Kumar
Consultant, Division of Hematology and Mark and Judy Mullins Professor of Hematological Malignancies, Mayo Clinic, Rochester, Minnesota
Dr. Kumar is the new Chair of the Myeloma, Amyloidosis and Dysproteinemia Disease Group at Mayo Clinic. He received his medical degree from the All India Institute of Medical Sciences, New Delhi, followed by his residencies in Internal Medicine there and at Mayo Clinic, where he also completed a hematology/oncology fellowship. His research is focused on developing new treatments for myeloma, including novel drug combinations and clinical trials ranging from phase I to III. Dr. Kumar also explores the progression mechanisms of plasma cell disorders and the impact of the bone marrow microenvironment on myeloma development. Dr. Kumar is Chair of the NCCN Multiple Myeloma Guidelines Panel and holds leadership roles in several international hematological societies. He is also the Editor in Chief of The Hematologist, the American Society of Hematology’s official newsletter.
Evangelos Terpos
Professor of Hematology and Director, Stem Cell Transplantation Unit, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Dr. Terpos specializes in the biology and management of bone disease in multiple myeloma and the application of modern imaging technologies like MRI and PET/CT. His research also focuses on minimal residual disease in plasma cell neoplasms. He has pioneered several clinical trials involving novel agents such as belantamab mafodotin and selinexor. An author of over 750 peer-reviewed papers, Dr. Terpos is highly cited with an h-index of 92 in ISI/Web of Knowledge and 112 in Google Scholar. He serves as a Councilor on the EHA Board, co-chairs the Bone Sub-Committee of the International Myeloma Working Group and is the Vice-President of the Greek Myeloma Study Group. Dr. Terpos is a frequent speaker at major international conferences, including ASH, ASCO, and EHA. He holds editorial roles at the American Journal of Hematology and Clinical Lymphoma, Myeloma & Leukemia, and is on the Editorial Board of Blood Cancer Journal.
Eirini Katodritou
Hematologist and Head, Department of Hematology-Oncology, Theagenion Cancer Hospital, Thessaloniki, Greece
Dr. Katodritou, a graduate of the Aristotle University of Thessaloniki, specializes in hematology and earned her PhD with a focus on Multiple Myeloma. As the Director of Hematology-Oncology at Theagenion Cancer Hospital, she leads the Clinical Trial Research Program for Multiple Myeloma and Lymphoma. Her scholarly work includes 109 peer-reviewed articles, garnering around 3,700 citations with an h-index of 32. Dr. Katodritou also serves as the Head of the Greek Myeloma Study Group, contributing significantly to research and clinical trials in the field.